To investigate the biochemical effects of oncogenic mutations of SHP2 on allosteric activation and inhibition, we purified a series of cancer-associated SHP2 mutants that exhibit a spectrum of basal phosphatase activity. This evidence concerns the gene PTPN11 and cancer.